Internal organ infections:Higher doses may be needed and for a long time.
Always follow your doctor's instructions, as they will adapt the treatment to your needs.
Use in Children
Itraconazole TecniGencapsules should not be used in children. Only in exceptional cases can it be prescribed by the doctor.
If you take moreItraconazole TecniGen100 mg hard capsules EFG than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or the Toxicological Information Service, Teléfono 91 562 04 20, indicating the medication and the amount used.
In case of accidental overdose, your doctor will apply supportive measures. They may also perform stomach lavage within the hour after ingestion or administer activated charcoal if considered appropriate. Itraconazole is not eliminated by hemodialysis. No specific antidotes are known.
If you forget to takeItraconazole TecniGen100 mg hard capsules EFG
Ifyouforgettotakethemedication,takethenextdosethatcorrespondstoyouandcontinuethetreatmentasindicatedbyyourdoctor.Do not take a double dose to compensate for the missed doses.
If you discontinue treatment withItraconazole TecniGen100 mg hard capsules EFG
Do not discontinue treatment withItraconazole TecniGenwithout consulting your doctor, as your symptoms may worsen or reappear.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
The following side effects have been seen during the marketing of the medicine and clinical trials.
Adverse reactions were classified by frequency using the following convention:
Very common: affects more than 1 in 10 patients
Common: affects between 1 and 10 in 100 patients
Uncommon: affects between 1 and 10 in 1,000 patients
Rare: affects between 1 and 10 in 10,000 patients
Very rare: affects less than 1 in 10,000 patients
Frequency not known: cannot be estimated with available data
•Blood and lymphatic system disorders
Rare: leucopenia
Frequency not known: neutropenia, thrombocytopenia (decrease in some blood cells)
•Immune system disorders
Uncommon: excessive and allergic hypersensitivity reactions.
Frequency not known: anaphylactic and anaphylactoid reactions, serum disease (allergy that appears after the injection of some sera and is characterized by the appearance of urticaria, accumulation of fluids, joint pains, fever, and extreme exhaustion), angioneuritic edema (swelling due to fluid accumulation that can affect the mouth and upper respiratory tract).
•Metabolism and nutrition disorders
Frequency not known: hypokalemia (decrease in potassium in the blood), increase in triglycerides.
•Nervous system disorders
Uncommon: paresthesia (tingling sensation in the extremities), headache, and dizziness.
Rare: decreased sensitivity (hypoesthesia)
Frequency not known: peripheral nerve damage
•Eye disorders
Rare: visual disturbances.
Frequency not known: blurred vision and double vision.
•Ear and labyrinth disorders
Rare: subjective sensation of noise in the ear.
Frequency not known: permanent or temporary hearing loss.
•Cardiac disorders
Frequency not known: congestive heart failure.
•Respiratory, thoracic, and mediastinal disorders
Rare: labored breathing, difficulty breathing (dyspnea)
Frequency not known: pulmonary edema, rhinitis (inflammation of the nasal mucosa that is characterized by the production of watery mucus, frequent sneezing, and nasal congestion), upper respiratory tract infection, sinusitis (irritation and swelling of the nasal sinuses).
•Gastrointestinal disorders
Common: abdominal pain, nausea
Uncommon: vomiting, discomfort associated with meals, diarrhea, constipation, unpleasant taste (bad taste in the mouth), accumulation of gas in the intestine (flatulence). Frequency not known: pancreatitis.
•Hepatobiliary disorders:
Uncommon: elevated bilirubin in the blood (hyperbilirubinemia), increased alanine aminotransferase and aspartate aminotransferase, liver function parameters.
Rare: reversible increase in liver enzymes
Frequency not known: acute liver failure, severe hepatotoxicity (including cases of severe acute liver failure), hepatitis, abnormal liver function.
•Skin and subcutaneous tissue disorders
Common: rash.
Rare: urticaria, alopecia (hair loss), pruritus.
Frequency not known: toxic epidermal necrolysis (severe skin disease characterized by skin rash and the appearance of blisters and scales), Stevens-Johnson syndrome (severe skin, mucous membrane, and eye inflammation), a severe skin disorder (generalized rash with skin peeling and blisters in the mouth, eyes, and genitals, or generalized rash with small pustules or blisters), erythema multiforme (skin disease characterized by the appearance of vesicles, blisters, etc.), exfoliative dermatitis (skin disease characterized by peeling), leukocytoclastic vasculitis (inflammation of the blood vessel walls), photosensitivity (exaggered skin response to sunlight), skin redness.
•Musculoskeletal and connective tissue disorders
Frequency not known: muscle pain or weakness, joint pain.
•Renal and urinary disorders
Rare: increased frequency of urination
Frequency not known: loss of urine.
•Reproductive and breast disorders
Uncommon: menstrual disorders
Frequency not known: erectile dysfunction.
•General disorders and administration site conditions
Uncommon: edema (fluid accumulation) Rare: fever.
•Injury, poisoning, and procedural complications
Frequency not known: injury.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C. Store in the original packaging to protect it from moisture.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
CompositionofItraconazol TecniGen100 mg hard capsules EFG
Appearanceof the product and contents of the packaging
The product is available in blister packaging of 7 and 14 hard capsules.
Only some sizes of packaging may be commercially marketed.
Holderof the marketing authorization and responsible for manufacturing: Holder of the marketing authorization:
Tecnimede España Industria Farmacéutica, S.A.
Avda. de Bruselas, 13, 3rd floor. Edificio América. Arroyo de la Vega Industrial Estate,
28108 Alcobendas (Madrid) Spain
Responsible for manufacturing:
Laboratorios Liconsa, S.A.
Avda. Miralcampo, Nº 7,
Miralcampo Industrial Estate
19200 Azuqueca de Henares (Guadalajara) SPAIN
This leaflet was approved inJune 2014.
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.